Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly. This activity will highlight the current indications, mechanism of action, dosage, contraindications, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) of tafamidis in a clinical setting pertinent for healthcare team members in the management of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) or peripheral neuropathy (ATTR-PN).

**Objectives:**
- Describe the mechanism of action of tafamidis.
- Review the available formulations and dosage of tafamidis.
- Identify the adverse events of tafamidis in clinical practice.
- Outline the importance of collaboration and coordination in an interprofessional health team to improve patient outcomes when receiving tafamidis.